Background
Prescribing in older people
Interventions to change prescribing
Study aim and objectives
Methods/design
Trial design
Study population
Recruitment and allocation
Intervention
Intervention component | Description |
---|---|
Academic detailing | A research pharmacist will visit the intervention practices. During the academic detailing, the pharmacist will: |
• Discuss the concept of PIP with the GPs, focusing on the prevalence and consequences of PIP in primary care | |
• Discuss the pharmaceutical treatment algorithm | |
• Discuss the medicines review process | |
• Demonstrate the web-based platform for accessing the pharmaceutical treatment algorithm for use in a medicines review with each participant patient | |
Medicines review with web-based pharmaceutical treatment algorithms | GPs will be asked to: |
• Schedule a medicines review for the patient’s next appointment | |
• Log on to the designated website using individualized user-names and passwords | |
• Access the individualized web-based pharmaceutical treatment algorithms for each patient during the review | |
• Conduct a medicines review following the page-by-page web-based pharmaceutical treatment algorithms. Each pharmaceutical treatment algorithm has the following structure: | |
Section A: The individual PIP with reason for concern | |
Section B: Alternative pharmacological and nonpharmacological treatment options | |
Section C: Background information (where relevant) | |
• Complete the process by submitting the review outcome form for each PIP per patient | |
Each GP will also be provided with a full, paper-based compendium of pharmaceutical treatment algorithms for reference | |
Patient information leaflets | For every alternative therapy option, a brief patient information leaflet has been written. These leaflets describe the PIP and the reasons why it may be inappropriate. They also outline the alternative therapies the GP may offer instead |
Control group: usual care with simple feedback
Contemporaneous national control HSE-PCRS dataset
Outcome measures
Criterion | Concern | Prevalence in Ireland* |
---|---|---|
PPI for peptic ulcer disease at full therapeutic dosage for >8 weeks | Earlier discontinuation or dose reduction for maintenance or prophylactic treatment of peptic ulcer disease, oesophagitis or GORD is indicated | 16.69% [11] |
7.68% [49] | ||
4.06% [10] | ||
NSAID (>3 months) for relief of mild joint pain in osteoarthritis | Simple analgesics are preferable and usually as effective for pain relief | 8.76% [11] |
1.05% [49] | ||
1.26% [10] | ||
Long-term (>1 month), long-acting benzodiazepines, for example, chlordiazepoxide, flurazepam, nitrazepam and clorazepate, and benzodiazepines with long-acting metabolites, for example, diazepam | Risk of prolonged sedation, confusion, impaired balance, falls | 5.22% [11] |
5.19% [49] | ||
3.00% [49] | ||
6.01% [10] | ||
9.09% [10] | ||
Any regular duplicate drug class prescription, for example, two concurrent opiates, NSAIDs, SSRIs, loop diuretics, ACE inhibitors. Excludes duplicate prescribing of drugs that may be required on a p.r.n. basis, for example, inhaled β2 agonists (long and short acting) for asthma or COPD, and opiates for management of breakthrough pain | Optimization of monotherapy within a single drug class should be observed prior to considering a new class of drug | 4.78% [11] |
2.18% [49] | ||
6.01% [10] | ||
TCAs with an opiate or calcium channel blocker | Risk of severe constipation | 2.05% [11] |
0.37% [49] | ||
Aspirin at dosage >150 mg/day | Increased bleeding risk, no evidence for increased efficacy | 1.69% [11] |
0.3% [49] | ||
0.14% [10] | ||
Theophylline as monotherapy for COPD or asthma | Risk of adverse effects due to narrow therapeutic index | 1.18% [11] |
0.56% [10] | ||
Use of aspirin and warfarin in combination without histamine H2 receptor antagonist (except cimetidine because of interaction with warfarin) or PPI | High risk of GI bleeding | 1.09% [11] |
0.3% [49] | ||
Doses of short-acting benzodiazepines, doses greater than: lorazepam (Ativan®), 3 mg; oxazepam (Serax®), 60 mg; alprazolam (Xanax®), 2 mg; temazepam (Restoril®), 15 mg; and triazolam (Halcion®), 0.25 mg | Total daily doses should rarely exceed the suggested maximums | 0.98% [49] |
1.54% [10] | ||
Prolonged use (>1 week) of first-generation antihistamines, that is, diphenhydramine, chlorpheniramine, cyclizine, promethazine | Risk of sedation and anticholinergic side-effects | 0.96% [11] |
0.15% [49] | ||
Warfarin and NSAID together | Risk of GI bleeding | 0.75% [11] |
1.68% [10] | ||
Calcium channel blockers with chronic constipation | May exacerbate constipation | 0.68% [49] |
0.28% [10] | ||
NSAID with history of peptic ulcer disease or GI bleeding, unless with concurrent histamine H2 receptor antagonist, PPI or misoprostol | Risk of peptic ulcer relapse | 0.67% [49] |
0.42% [10] | ||
Bladder antimuscarinic drugs with dementia | Risk of increased confusion, agitation | 0.46% [11] |
0.84% [10] | ||
TCAs with constipation | May worsen constipation | 0.45% [49] |
0.14% [10] | ||
Digoxin at a long-term dosage >125 μg/day (with impaired renal function) | Increased risk of toxicity | 0.36% [11] |
0.15% [49] | ||
0.55% [10] | ||
Thiazide diuretic with a history of gout | May exacerbate gout | 0.36% [11] |
0.45% [49] | ||
0.14% [10] | ||
Glibenclamide (with type 2 diabetes mellitus) | Risk of prolonged hypoglycaemia | 0.29% [11] |
0.22% [49] | ||
Aspirin with a past history of peptic ulcer disease, without histamine H2 receptor antagonist or PPI | Risk of bleeding | 0.22% [49] |
0.28% [10] | ||
Prochlorperazine (Stemetil®) or metoclopramide with parkinsonism | Risk of exacerbating parkinsonism | 0.21% [11] |
TCAs with dementia | Risk of worsening cognitive impairment | 0.18% [11] |
0.28% [10] | ||
TCAs with glaucoma | Likely to exacerbate glaucoma | 0.14% [11] |
0.07% [49] | ||
TCAs with cardiac conductive abnormalities | Pro-arrhythmic effects | 0.14% [10] |
Long-term corticosteroids (>3 months) as monotherapy for rheumatoid arthritis or osteoarthritis | Risk of major systemic corticosteroid side-effects | 0.14% [10] |
Bladder antimuscarinic drugs with chronic prostatism | Risk of urinary retention | 0.14% [10] |
NSAID with heart failure | Risk of exacerbation of heart failure | 0.07% [49] |
0.14% [10] | ||
TCAs with prostatism or prior history of urinary retention | Risk of urinary retention | 0.07% [49] |
0.14% [10] | ||
Systemic corticosteroids instead of inhaled corticosteroids for maintenance therapy in COPD or asthma | Unnecessary exposure to long-term side-effects of systemic steroids | 0.07% [49] |
0.56% [10] | ||
Bladder antimuscarinic drugs with chronic glaucoma | Risk of acute exacerbation of glaucoma | <0.01% [11] |
NSAID with SSRI | Increased risk of GI bleeding | N/A |
Bladder antimuscarinic drugs with chronic constipation | Risk of exacerbation of constipation | N/A |
Prednisolone (or equivalent) > 3 months or longer without bisphosphonate | Increased risk of fracture | N/A |
NSAID with ACE-inhibitor | Risk of kidney failure, particularly with the presence of general arteriosclerosis, dehydration or concurrent use of diuretics | N/A |
NSAID with diuretic | May reduce the effect of diuretics and worsen existing heart failure | N/A |
Secondary outcome | Measure |
---|---|
Drug-specific outcomes | The absolute number of PIPs per patient of the top five occurring PIP drugs: [11] |
Proton pump inhibitor (PPI) for peptic ulcer disease at full therapeutic dosage for >8 weeks | |
Long-term (>3 months) use of NSAIDs for relief of mild joint pain in osteoarthritis | |
Long-term (>1 month) use of long-acting benzodiazepines, for example, chlordiazepoxide, flurazepam, nitrazepam, chlorazepate and benzodiazepines with long-acting metabolites for example, diazepam | |
Any regular duplicate drug class prescription | |
TCAs with an opiate or calcium channel blocker | |
Mean number of PIPs per patient of the top five PIP drugs (as above) | |
Patient-reported outcomes | Health status (EQ-5D) |
Patients’ Beliefs about Medicine Questionnaire (BMQ) | |
Well-being Questionnaire (WBQ-12) | |
Process-of-care measures | Number of GP visits (6 months prior to enrolment and at 4 and 12 month follow-up) |
Number of hospital admissions (6 months prior to enrolment and at 4 and 12 month follow-up | |
Process evaluations | Decisions made per PIP |
Number of times alternatives were prescribed | |
Reported primary reason for decision made for example, risks outweigh benefits, patient preference, hospital/consultant initiated |